Evidence map›Paper›PMID 42855524›Full record

ArticleHypertension research : official journal of the Japanese Society of Hypertension2026

Efficacy and safety of esaxerenone versus angiotensin II receptor blockers in older patients with hypertension, with and without type 2 diabetes mellitus: a predefined subgroup analysis of the ESCORT-HT study.

Mitsuru Ohishi, Kazuomi Kario, Hiroyuki Ohbayashi, Hajime Ishii, Mitsutoshi Kato, Minoru Nozaki, Norio Abiru, Toshiki Fukui, Kazushi Nomura, Yasushi Fukushima and 13 more

Abstract read
PubMed Publisher
In one paragraph

Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Mitsuru OhishiDepartment of Cardiovascular Medicine and Hypertension, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima-city, Japan. ohishi@m2.kufm.kagoshima-u.ac.jp.
Kazuomi KarioDivision of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Shimotsuke, Japan.
Hiroyuki OhbayashiTohno Chuo Clinic, Mizunami, Japan.
Hajime IshiiKashinoki Clinic, Date, Fukushima, Japan.
Mitsutoshi KatoKato Clinic of Internal Medicine, Katsushika-ku, Tokyo, Japan.
Minoru NozakiMedical Corporation Shirayurikai Swing Nozaki Clinic, Musashino, Tokyo, Japan.
Norio AbiruMidori Clinic, Nagasaki-city, Japan.
Toshiki FukuiOlive Takamatsu Medical Clinic, Takamatsu, Kagawa, Japan.
Kazushi NomuraNomura Clinic, Itabashi-ku, Tokyo, Japan.
Yasushi FukushimaFukuwa Clinic, Chuo-ku, Tokyo, Japan.
Naoki ItabashiItabashi Diabetes and Dermatology Medical Clinic, Koga, Ibaraki, Japan.
Kazuaki UchiyamaUchiyama Clinic, Joetsu, Niigata, Japan.
Masafumi NishizawaMinamisanriku Hospital, Motoyoshi, Miyagi, Japan.
Yoshiki HataMinamino Cardiovascular Hospital, Hachioji, Tokyo, Japan.
Noriko NakamuraPrimula Clinic, Kagoshima-city, Japan.
Satoshi KodonoFukuhama Chuo Clinic, Fukuoka-city, Japan.
Kunio HiranoHirano Clinic, Morioka, Iwate, Japan.
Tomohiro KatsuyaKatsuya Clinic, Amagasaki, Hyogo, Japan.
Tatsuo ShimosawaDepartment of Clinical Laboratory, School of Medicine, International University of Health and Welfare, Narita, Chiba, Japan.
Kazuhito ShiosakaiData Intelligence Department, Daiichi Sankyo Co., Ltd., Shinagawa-ku, Tokyo, Japan.
Taketoshi FurugoriMedical Affairs Planning Science Department, Medical Affairs Division, Daiichi Sankyo Co., Ltd., Chuo-ku, Tokyo, Japan.
Takashi TaguchiMedical Evidence Department, Medical Affairs Division, Daiichi Sankyo Co., Ltd., Chuo-ku, Tokyo, Japan.
ESCORT-HT investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This predefined subgroup analysis of the ESCORT-HT study evaluated the antihypertensive efficacy, organ-protective effects, and safety profile of esaxerenone compared with an angiotensin II receptor blocker (ARB) in patients aged ≥65 years with hypertension on amlodipine, stratified by the presence or absence of type 2 diabetes mellitus (T2DM). In the T2DM subgroup, 65 patients received esaxerenone and 55 received an ARB. In the non-T2DM subgroup, 135 and 145 patients received these treatments, respectively. The least squares mean change from baseline at the end of treatment in morning home systolic blood pressure in the T2DM subgroup was -10.9 (95% confidence interval -13.5, -8.4) mmHg in esaxerenone-treated patients and -8.8 (-11.5, -6.0) mmHg in ARB-treated patients; in the non-T2DM subgroup, these were -10.5 (-12.3, -8.7) mmHg and -9.1 (-10.8, -7.3) mmHg, respectively. Although this subgroup analysis was not powered to formally demonstrate non-inferiority, the between-treatment differences in morning home SBP were consistent with the non-inferiority of esaxerenone to ARBs based on the margin used in the primary analysis in both the T2DM and non-T2DM subgroups. Urinary albumin-to-creatinine ratio (UACR) significantly decreased in esaxerenone-treated patients with T2DM (-33.4%), but not in those without T2DM. In contrast, UACR significantly decreased in ARB-treated patients without T2DM (-21.2%), but not in those with T2DM. One esaxerenone-treated patient in the non-T2DM subgroup had a serum potassium level ≥6.0 mEq/L, and a low proportion of esaxerenone-treated patients in the non-T2DM subgroup had hypokalemia (2.2%). Overall, this subgroup analysis showed favorable antihypertensive and kidney-protective effects (based on UACR) of esaxerenone, combined with an acceptable safety profile, in patients with hypertension. Moreover, antihypertensive effects were observed regardless of T2DM status, supporting the use of esaxerenone in older patients with hypertension and comorbid T2DM.

Indexed as

Angiotensin II receptor blockerEsaxerenoneMorning hypertensionSubgroup analysisType 2 diabetes mellitus

Identifiers

PMID42855524

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.